Jump to content
  • Sign Up
Scott Adams

Alba Therapeutics' Phase Iib Trial In Celiac Disease Meets Primary Endpoint - Pharmabiz.com

Rate this topic

Recommended Posts

Alba Therapeutics' phase IIb trial in celiac disease meets primary endpoint


Alba Therapeutics Corporation, a privately held, clinical-stage biopharmaceutical company, announced positive results of phase IIb trial evaluating its investigational product, larazotide acetate, a first-in-class tight junction regulator, which is ...

View the full article

Share this post

Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...